Per Edelmann

Axantia is the holding company of Pharma International - Jordan, and Med City Pharma - Saudi Arabia Axantia is a regional leader in generic medicines committed to improving health outcomes, cost of care, and the general wellbeing of patients; all with a focus on creating a brand synonymous with quality.

Neuraxpharm is the leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders. It has a unique understanding and in-depth knowledge of the CNS market built over 35 years. Neuraxpharm is constantly innovating, with new products and solutions to address unmet patient needs and is expanding its portfolio through its pipeline, partnerships and acquisitions. The company has more than 1,000 employees and develops and commercializes CNS products through a direct presence in more than 20 countries in Europe, two in Latin America, and globally via partners in more than 40 countries. Neuraxpharm is backed by funds advised by the global private equity firm, Permira. Neuraxpharm manufactures part of its pharmaceutical products at Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in Spain. To learn more about Neuraxpharm, please visit https://www.neuraxpharm.com

A global private markets firm. 30+ years of unlocking returns and growth for investors beyond public markets.

Pharmaceutical Development and Contract Manufacturer (CDMO) of small- and medium- volume parenteral solutions, in ampoules, pre-filled syringes (polypropylene or glass), vials, lyophilisation, as well as sterile solutions in blow-fill-seal (BFS) containers. Mefar offers full service Pharmaceutical CDMO services to wide range of local and Fortune 500 Pharmaceutical companies from solution preparation, aseptic filling, packaging, cold chain management and serialization. Mefar also has full service analytical labs performing scale up batches to stability studies and technology transfer. Mefar has certifications from the Turkish Health Authority, EMA, SFDA, Russian, and total of more than 10 GMP certifications. To learn more, we invite you to check out our website www.mefar.com and view our introductory movie or e mail us business@mefar.com

Impilo is a Nordic investment company focused solely on investments in companies operating in the pharmaceutical, medical technology, healthcare services and other health-related industries. Our starting point is that our portfolio companies must contribute to a positive and sustainable development of the communities and markets in which they operate in order to remain successful in the long term. This is a conviction that is embedded in our investment strategy since it necessitates a deeper understanding and reduces risks. This way, Impilo invests in people’s opportunities to enjoy healthier lives in the future.

Acino is a Swiss pharmaceutical company headquartered in Zurich, with a clear focus on selected markets in the Middle East, Africa, the CIS Region, Russia and Latin America. We deliver quality pharmaceuticals to promote affordable healthcare in these emerging markets and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing. For more information: www.acino.swiss *** By engaging with Acino on LinkedIn (or any other Acino social media channel), you are agreeing to our Social Media Community Guidelines. If you do not agree to them, do not engage with Acino on social media. Please read our detailed community guidelines carefully here: https://acino.swiss/acino_social_media_community_guidelines_may2022 ***

We are the UKs development finance institution and impact investor, backed by the UK Government. With over 75 years’ experience, we are a trusted investment partner to businesses in Africa, Asia and the Caribbean. We invest to create more productive, sustainable and inclusive economies, enabling people to build better lives for themselves and their communities. We currently partner with nearly 1,500 businesses, working with our investees to help them succeed and grow impactful businesses.